Acute lymphoblastic leukemia in elderly: Prognosis and treatment;Leucémie aiguë lymphoblastique du sujet âgé: Pronostic et traitement

Bulletin du Cancer

Volumn 91, Issue 9, 2004, Pages 713-720

  Thomas, Xavier ^a   Tavernier, Emmanuelle ^a   Le, Quoc Hung ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukemia; Chemotherapy; Elderly; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE DISTRIBUTION; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; DISEASE DURATION; DRUG CYTOTOXICITY; HUMAN; LYMPHOCYTE SUBPOPULATION; PHILADELPHIA 1 CHROMOSOME; PROGNOSIS; PROLYMPHOCYTE; REVIEW; SENESCENCE; SURVIVAL RATE;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIPOSOMES; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION;

EID: 6044260214     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Kebriaei P, Anastasi J, Larson RA. Acute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol 2002 ; 15 : 597-621.
2. Sandler DP, Ross JA. Epidemiology of acute leukemia in children and adults. Semin Oncol 1997 ; 24 : 3-10.
3. Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997 ; 24 : 70-82.
4. Taylor PR, Reid MM, Proctor SJ. Acute lymphoblastic leukemia in the elderly. Leuk Lymphoma 1994 ; 13 : 373-80.
5. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the Gimema ALL 0288 randomized study. Blood 2002 ; 99 : 863-71.
6. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000 ; 27 : 540-59.
7. Farhi DC, Rosenthal NS. Acute lymphoblastic leukemia. Clin Lab Med 2000 ; 20 : 17-28.
8. Kebriaei P, Larson RA. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol 2003 ; 10 : 284-9.
9. Gaynor J, Chapman D, Little C, McKenzie S, Miller W, Andreeff M, et al. A cause specific hazard rate analysis of prognostic factor among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969. J Clin Oncol 1988 ; 6 : 1014-30.
10. Bassan R, Battista R, D'Emilio A, Viero P, Dragone P, Dini E, et al. Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia. Eur J Cancer 1991 ; 27 : 441-7.
11. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P et al. Cancer and Leukemia Group B study 8811. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia. Blood 1995 ; 85 : 2025-37.
12. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000 ; 18 : 547-61.
13. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and mantenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002 ; 16 : 1259-66.
14. Taylor PR, Reid MM, Bown N, Hamilton PJ, Proctor SJ. Acute lymphoblastic leukemia in patients aged 60 years and over: A population-based study of incidence and outcome. Blood 1992 ; 80 : 1813-7.
15. Kantarjian HM, O'Brien S, Smith T, Estey EH, Beran M, Preti A, et al. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol 1994 ; 88 : 94-100.
16. Thomas X, Le QH. Stratégies thérapeutiques actuelles dans les leucémies aiguës lymphoblastiques de l'adulte. Bull Cancer 2003 ; 90 : 833-50.
17. Annino L, Goekbuget N, Delannoy A. Acute lymphoblastic leukemia in elderly. Hematol J 2002 ; 3 : 219-33.
18. Späth-Schwalbe E, Heil G, Heimpel H. Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period. Ann Hematol 1994 ; 69 : 291-6.
19. Pagano L, Mele L, Casorelli I, Fianchi L, Di Febo A, Leone G. Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study. Haematologica 2000 ; 85 : 1327-9.
20. Ferrari A, Annino L, Crescenzi S, Romani C, Mandelli F. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia 1995 ; 9 : 1643-7.
21. Mandelli F, Annino L, Ferrari A, for the Gimema Group. ALL in the elderly: the GIMEMA trials. Ann Hematol 1995 ; 70 (suppl.2) : 41.
22. Nagura E, Minami S, Nagata K, Morishita Y, Takeyama H, Sao H, et al. Analysis of elderly patients, aged 60 year old or older, with acute lymphoblastic leukemia. Nippon Ronen Igakkai Zasshi 1999 ; 36 : 52-8.
23. Legrand O, Marie JP, Marjanovic Z, Cadiou M, Blanc C, Ramond S, et al. Prognostic factors in elderly acute lymphoblastic leukaemia. Br J Haematol 1997 ; 97 : 596-602.
24. Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989 ; 73 : 57-63.
25. Bassan R, Di Bona E, Lerede T, Pogliani E, Rossi G, D'Emilio A, et al. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Leuk Lymphoma 1996; 22 : 295-301.
26. Thomas X, Olteanu N, Charrin C, Lhéritier V, Magaud JP, Fiere D. Acute lymphoblastic leukemia in the elderly: The Edouard Herriot Hospital experience. Am J Hematol 2001 ; 67 : 73-83.
27. Yenerel MN, Atamer T, Yavuz AS, Kucukkaya R, Besisik S, Aktan M, et al. Myeloid antigen expression provides favorable outcome in patients with adult acute lymphoblastic leukemia: a single-center study. Ann Hematol 2002 ; 81 : 498-503.
28. Secket-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 1997 ; 96 : 601-10.
29. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukaemia Group B experience. Blood 1999 ; 93 : 3983-93.
30. Faderl S, Kantarjian HM, Thomas DA, Cortes J, Giles F, Pierce S, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000 ; 36 : 263-73.
31. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Biaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood 2002 ; 100 : 2357-66.
32. Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002 ; 99 : 1536-43.
33. Charrin C. A Collaborative Study of the Groupe Français de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute Lymphoblastic leukemia: correlations with hematologic findings and outcome. Blood 1996 ; 87 : 3135-42.
34. Delannoy A, Cazin B, Thomas X, Bouabdallah R, Boiron JM, Huguet F, et al. Treatment of acute lymphocytic leukemia in the elderly: an evaluation of vindesine during induction and of interferon alpha given as a single agent after comlete remission. Leak Lymphoma 2002 ; 43 : 75-81.
35. Offidani M, Corvatta L, Centurioni R, Leoni F, Malerba L, Mele A, et al. High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. Hematol J 2003 ; 4 : 47-53.
36. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance. Leukemia 1991 ; 5 : 196-9.
37. Preti A, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med 1994 ; 97 : 60-5.
38. Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JWG, Gökbuget N, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996 ; 95 : 678-91.
39. Thomas X, Thiebaut A, Olteanu N, Danaïla C, Charrin C, Archimbaud E, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 1998 ; 40 : 119-28.
40. Götz G, Weh HJ, Walter TA, Kuse R, Kolbe K, Dolken G, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol 1992 ; 64 : 97-100.
41. Kantarjian H, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 1991 ; 78 : 2411-8.
42. Radich J, Gehly G, Lee A, Avery R, Bryant E, Edmands S, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997 ; 89 : 2602-9.
43. Fiere D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP, et al. Adult acute lymphoblastic leukemia : a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993 ; 11 : 1990-2001.
44. Bloomfield CD, Peterson LC, Yunis JJ, Brunning RD. The Philadelphia chromosome in adults presenting with acute leukemia: A comparison of Ph1+ and Ph1-patients. Br J Haematol 1977 ; 36 : 347-58.
45. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B study (8762). Blood 1992 ; 80 : 2983-90.
46. Mandelli F, Annino L, Ciolli S, Fabbiano F, Fanin R, Fioritoni G, et al. Philadelphia chromosome (Ph 1) positive acute lymphoblastic leukemia (ALL) in adults: Interim results of GIMEMA ALL 0288 pilot study. Blood 1993 ; 82 (suppl.1): 58a.
47. Annino L, Ferrari A, Cedrone M, Giona F, Lo Coco F, Meloni G, et al. Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia: Experience of treatments during a ten-year period. Leukemia 1994 ; 8 : 664-7.
48. Sierra J, Radich J, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J, et al. Marrow Transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997 ; 90 : 1410-4.
49. Snyder DS, Nademanee AP, O'Donnell MR, Parker PM, Stein AS, Margolin K, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999 ; 13 : 2053-8.
50. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treament in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000 ; 342 ; 998-1006.
51. Houot R, Tavernier E, Le QH, Lhéritier V, Thiebaut A, Thomas X. Philadelphia chromosome-positive acute lymphoblastic leukaemia in the elderly : prognostic factors and treatment outcome. Hematology 2004 ; (in press).
52. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004 (in press).
53. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003 ; 98 : 1337-54.
54. Robak T, Szmigielska-Kaplon A, Wrzesien-Kus A, Wierzbowska A, Skotnicki AB, Piatkowska-Jakubas, et al. Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience. Ann Hematol 2004 (in press).
55. Delannoy A, Sebban C, Cony-Makhoul P, Cazin B, Cordonnier C, Bouabdallah R, et al. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. Leukemia 1997 ; 11 : 1429-34.
56. Goasguen JE, Dossot JM, Fardel O. Expression of the multidrug resistance associated P-glycoprotein (P-170) in 59 cases of acute lymphocytic leukemia: prognostic implications. Blood 1993 ; 81 : 2394-8.
57. Delannoy A, Ferrant A, Bosly A, Chatelain C, Doyen C, Martiat P, et al. Acute lymphoblastic leukemia in the elderly. Eur J Haematol 1990 ; 45 : 90-3.
58. Sorensen JT, Gerald K, Bodensteiner D, Holmes EF. Effect of age on survival in acute leukemia. 1950-1990. Cancer 1993 ; 72 : 1602-6.
59. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001 ; 344 : 1038-42.
60. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002 ; 1 : 31-6.
61. Ottmann OG, Wassmann B. Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002 ; 15 : 757-69.
62. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al. A phase 2 study of Imatinib in patients with relapse or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002 ; 100 : 1905-71.
63. Thomas DA, Cortes J, Kantarjian HM. New agents in the treatment of acute lymphocytic leukaemia. Best Pract Res Clin Haematol 2002 ; 15 : 771-90.
64. Wassmann B, Gokbuget N, Scheuring UJ, Binckebanck A, Reutzel R, Gschaidmeier H, Hoelzer D, et al. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Ann Hematol 2003 ; 82 : 716-20.
65. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of ST571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000 ; 96 : 3195-9.
66. LeCoutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 ; 95 : 1758-66.
67. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000 ; 96 : 1070-9.
68. Dyer MJ, Hale G, Hayhoe FG. Effect of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73 : 1431-9.
69. Faderl S, Kantarjian HM, O'Brien S, Cortes J, Thomas DA, Giles F, et al. A broad exploratory trial of Campath-1H in the treatment of acute leukemias. Blood 2000 ; 96 : 324a.
70. Thomas D, Cortes J, Giles F, Faderl S, O'Brien S, Garcia-Manero G, et al. Rituximab and hyper-CVAD for adult Burkitt's (BL) or Burkitt's-like (BLL) leukemia or lymphoma. Blood 2001 ; 98 (suppl.1) : 804a.
71. Szatrowski TP, Larson RA, Dodge R, Sklar J, Reynolds C, Westbrook CA, et al. The effect of anti-B4-blocked Ricin (anti-B4-BR) on minimal residual disease (MRD) in adults with B-lineage acute lymphoblastic leukemia (ALL) (CALGB 9311, 8762, 8763). Blood 1996 ; 88 : 669a.
72. Messinger Y, Levine A, Fuchs E, Goldman F, Uckun FM. B34 (anti-CD19)-Genistein treatment of therapy refractory B-lineage acute lymphoblastic leukemia. Blood 1998 ; 92 : 2530a.
73. Thomas DA, Sarris A, O'Brien S, Cortes J, Giles FJ, Faderl S, et al. Phase II study of liposomal vincristine (LIPOV) in relapsed or refractory adult acute lymphoblastic leukemia (ALL). Blood 1999 ; 94 (suppl.1) : 238b.
74. Krishna R, Webb MS, St Onge G, Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Therap 2001 ; 298 : 1262-1212.
75. Cortes J, O'Brien S, Estey E. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs 1999 ; 17 : 81-7.
76. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999 ; 457 : 621-9.
77. Frankel SR, Kurtzberg J, DeOleivera D, Dodge R, Peterson B, Powell BL, et al. Toxicity and pharmacokinetics of PEG-asparaginase (PEG-asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL). CALGB 9511. Blood 1996 ; 88 (suppl. 1) : 669a.
78. Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer 1999 ; 86 : 1203-9.
79. Avivi I, Rowe JM, Goldstone AH. Stem cell transplantation in adult ALL patients. Best Pract Res Clin Haematol 2002 ; 15 : 653-74.
80. Massenkeil G, Nagy M, Lawang M, et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high risk acute leukemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003 ; 31 : 339-45.
81. Giralt S, Anagnastopoulos A, Shahjahanan M, Champlin R. Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol 2002 ; 39 : 57-66.